Comment on this story

2 Comments on this story



Post comments

Email to a friend




Send email

Related Jobs

Sanofi claims positive dronedarone data

12 Nov 2008

Clinical Research

Sanofi-aventis has reported positive data from a clinical study of dronedarone, which goes by the brand-name Multaq.

The French company stated an analysis of data from the Athena study showed dronedarone "significantly reduced" both the number and duration of hospital visits among patients with atrial fibrillation or atrial flutter (AF/AFL).

Hospital stays are said to have been decreased by 28 per cent and duration of stays for cardiovascular reasons by 35 per cent when compared to placebo.

"This study demonstrates both significant rhythm and rate-controlling properties of dronedarone in the Athena population, which consisted of higher-risk patients with atrial fibrillation," commented Dr Richard Page, professor and head of the division of cardiology at the University of Washington School of Medicine.

Meanwhile, the company's vaccines division Sanofi Pasteur has revealed its polio immunisation product has been chosen by the Russian authorities for the country's national vaccination programme.

The company said four million doses of IPV Imovax Polio have so far been delivered since Russia began its Project Health scheme in the summer.


Bookmark and Share

2 comments on this story

keith sillitoe says:

17 November 2008 at 03:20 PM

I like welshmike have atrial fibrillation. I would be interested to know when this drug will be available in the uk and also if this would result in less need to take warfarin

welshmike says:

16 November 2008 at 05:08 PM

I have paroxysmal atrial fibrillation and am currently taking olmesartan medoxomil, warfarin and bisoprolol and look forward to Mukltaq being available.